CAMBRIDGE, Mass., Feb. 28,
2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a
clinical-stage biopharmaceutical company focused on
creating precisely targeted therapies for
clinically proven kinase targets in cancer, today announced that
James Porter, Ph.D., Chief Executive
Officer, and Alexandra Balcom, Chief
Financial Officer, will participate in fireside chats during the
following March investor conferences:
- TD Cowen 45th Annual Health Care Conference
on Wednesday, March 5, 2025 at
9:50 a.m. ET in Boston;
- Leerink Global Healthcare Conference 2025 on
Monday, March 10, 2025 at
10:40 a.m. ET in Miami, FL; and,
- Barclays 27th Annual Global Healthcare
Conference on Wednesday, March 12,
2025 at 2:30 p.m. ET in
Miami, FL.
Live webcasts will be available in the Investors section of the
company's website at www.nuvalent.com, and archived for 30
days following the presentations.
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a
clinical-stage biopharmaceutical company focused on
creating precisely targeted therapies for patients
with cancer, designed to overcome the limitations of existing
therapies for clinically proven kinase targets. Leveraging deep
expertise in chemistry and structure-based drug design, we develop
innovative small molecules that have the potential to overcome
resistance, minimize adverse events, address brain metastases, and
drive more durable responses. Nuvalent is advancing a robust
pipeline with investigational candidates for ROS1-positive,
ALK-positive, and HER2-altered non-small cell lung cancer, and
multiple discovery-stage research programs.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-upcoming-march-investor-conferences-302388052.html
SOURCE Nuvalent, Inc.
